SHINE Technologies has submitted its drug master file to the FDA for a material used in precision cancer treatment.
The Janesville-based company yesterday announced the submission for non-carrier added lutetium-177 chloride, or Lu-177. This radiopharmaceutical is used alongside a cancer-seeking molecule to attack cancer cells, and is “especially useful” against prostate cancer, according to the r...
Please log in to access subscriber content.
If you don't have a subscription, please contact schmies@wispolitics.com for subscription options on the WisPolitics-State Affairs platform, which is the new home for WisPolitics subscriber products.
